Johnson & Johnson to acquire Aragon Pharmaceuticals

According to a media release issued by the company earlier today, Johnson & Johnson has made a definitive agreement to acquire Aragon Pharmaceuticals, Inc., including all rights to Aragon’s androgen receptor antagonist program.

In particular, this means that Johnson & Johnson gains all rights to the second generation androgen receptor signaling inhibitor ARN-509, which is currently in Phase II development for the treatment of castration-resistant prostate cancer (CRPC) … and has shown significant promise as a treatment for advanced forms of prostate cancer.

This also means that Johnson & Johnson will have a potential “follow-up” product to abiraterone acetate (Zytiga) when that drug loses patent protection in the not too distant future.

Apparently Johnson & Johnson is only interested in Aragon’s androgen receptor antagonist program. The deal, as announced, allows Aragon to transfer all of its other assets to a newly formed company which Aragon will spin off before the deal is consummated. A senior executive with global responsibility for the Johnson & Johnson oncology business is quoted as stating, “Prostate cancer is one of our main areas of focus, and we are pleased to be adding ARN-509 to our portfolio.”

2 Responses

  1. Aragon

  2. Ooops … Thanks … Fixed above …

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: